Association between the expression of inhibitor of growth family member 4 and the progression of clear cell renal carcinoma

Ren,Yuxin; Zhao,Song; Chen,He; Fu,Ying‑Mei; Zhao,Bai

doi:10.3892/ol.2017.6450

Association between the expression of inhibitor of growth family member 4 and the progression of clear cell renal carcinoma

Authors:
- Yuxin Ren
- Song Zhao
- He Chen
- Ying‑Mei Fu
- Bai Zhao
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Pathology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of Pharmacology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of Urology Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China
Published online on: June 21, 2017 https://doi.org/10.3892/ol.2017.6450
Pages: 2453-2457

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibitor of growth family member 4 (ING4) is a candidate tumor suppressor that serves important roles in tumor growth and angiogenesis. In the present study ING4 expression was assessed in clear cell renal carcinoma (CCRC) tissues and its association with the progression of CCRC was determined. The expression of ING4 in 125 patients with CCRC was analyzed using reverse transcription-quantitative polymerase chain reaction (RT‑qPCR), western blot analysis and immunohistochemical methods. A total of 40 adjacent normal renal tissues were used as control samples. The results identified that ING4 expression was positive in 100% of normal renal tissues, but in only 82.3% CCRC samples. RT‑qPCR and western blotting results demonstrated that expression levels of ING4 mRNA and protein were significantly decreased in CCRC compared with in normal tissues (P<0.0001). ING4 expression was not associated with sex, age or tumor volume (P>0.05), but was associated with the nuclear grade of renal cancer (P<0.0001), the clinical stage of CCRC (P<0.0001) and lymphatic metastasis (P<0.0001). The results of the present study indicated that dysregulation of ING4 expression may be involved in the initiation and progression of CCRC.

View Figures

View References

1	Garkavtsev I, Kazarov A, Gudkov A and Riabowol K: Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genetics. 14:415–420. 1996. View Article : Google Scholar : PubMed/NCBI
2	Garkavtsev I and Riabowol K: Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33ING1 candidate tumor suppressor. Mol Cell Biol. 17:2014–2019. 1997. View Article : Google Scholar : PubMed/NCBI
3	Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH and Jain RK: The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
4	Gunduz M, Nagatsuka H, Demircan K, Gunduz E, Cengiz B, Ouchida M, Tsujigiwa H, Yamachika E, Fukushima K, Beder L, et al: Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene. 356:109–117. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kim S, Chin K, Gray JW and Bishop JM: A screen for genes that suppress loss of contact inhibition: Identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci USA. 101:pp. 16251–16256. 2004; View Article : Google Scholar : PubMed/NCBI
6	Guo Y, Meng X, Wang Q, Wang Y and Shang H: The ING4 binding with p53 and induced p53 acetylation were attenuated by human papillomavirus 16 E6. PLoS One. 8:e714532013. View Article : Google Scholar : PubMed/NCBI
7	Masayuki S, Makoto N, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J and Harris CC: p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 63:2373–2378. 2003.PubMed/NCBI
8	Liu E, Wu J, Cao W, Zhang J, Liu W, Jiang X and Zhang X: Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol. 85:263–270. 2007. View Article : Google Scholar : PubMed/NCBI
9	Russell M, Berardi P, Wei G and Riabowol K: Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res. 312:951–961. 2006. View Article : Google Scholar : PubMed/NCBI
10	Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K, Yokota J and Harris CC: A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene. 22:343–350. 2003. View Article : Google Scholar : PubMed/NCBI
11	Tapia C, Zlobec I, Schneider S, Kilic E, Güth U, Bubendorf L and Kim S: Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol. 42:983–990. 2011. View Article : Google Scholar : PubMed/NCBI
12	Wang QS, Li M, Zhang LY, Jin Y, Tong DD, Yu Y, Bai J, Huang Q, Liu FL, Liu A, et al: Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology. 57:271–281. 2010. View Article : Google Scholar : PubMed/NCBI
13	Organization WH, Ferlay J, Pisani P and Parkin DM: Globocan 2000: Cancer incidence, mortality and prevalence worldwide. Bray Freddie. 2001.
14	Zbar B, Klausner R and Linehan WM: Studying cancer families to identify kidney cancer genes. Annu Rev Med. 54:217–233. 2003. View Article : Google Scholar : PubMed/NCBI
15	Fang F, Luo LB, Tao YM, Wu F and Yang L: Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 18:409–416. 2009. View Article : Google Scholar : PubMed/NCBI
16	Cai L, Li X, Zheng S, Wang Y, Li H, Yang J and Sun J: Inhibitor of growth 4 is involved in melanomagenesis and induces growth suppression and apoptosis in melanoma cell line M14. Melanoma Res. 19:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
17	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Zhao W, Yang L, Wang L, Zuo W, Yuan S, Yu J, Yu Q, Hu X, Wang S, Liu N, et al: Primary clear cell carcinoma of nasal cavity: Report of six cases and review of literature. Int J Clin Exp Med. 7:5469–5476. 2014.PubMed/NCBI
20	Zhang X, Wang KS, Wang ZQ, Xu LS, Wang QW, Chen F, Wei DZ and Han ZG: Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun. 331:1032–1038. 2005. View Article : Google Scholar : PubMed/NCBI
21	Li M, Jin Y, Sun WJ, Yu Y, Bai J, Tong DD, Qi JP, Du JR, Geng JS, Huang Q, et al: Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol. 219:87–95. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yang HC, Sheng WH, Xie YF, Miao JC, Wei WX and Yang JC: In vitro and in vivo inhibitory effect of Ad-ING4 gene on proliferation of human prostate cancer PC-3 cells. Ai Zheng. 28:1149–1157. 2009.(In Chinese). PubMed/NCBI
23	Raho G, Miranda C, Tamborini E, Pierotti MA and Greco A: Detection of novel mRNA splice variants of human ING4 tumor suppressor gene. Oncogene. 26:5247–5257. 2007. View Article : Google Scholar : PubMed/NCBI
24	Bleumer I, Oosterwijk E, De Mulder P and Mulders PF: Immunotherapy for renal cell carcinoma. Eur Urol. 44:65–75. 2003. View Article : Google Scholar : PubMed/NCBI